Webinars
-
37:25
Put your challenging affinity screening campaigns back on track — after you’ve tried everything else
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
-
25:08
Overcome bottlenecks in viral vector manufacturing
The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developi
-
21:48
How to improve outcomes of your viral vectors for gene therapy with high-quality data from biophysical profiling methods
Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns such as serotype, storage stability, expression method, and genetic fill level must be addres
-
32:05
Tour Andromeda: how to screen for optimal expression of folded membrane proteins in crude lysate
Poor expression levels, solubilization, and stability — these are the daily challenges that your membrane protein production team faces every day. You go through long cycles of expression optimization
-
25:16
The autocorrelation function: the key to understanding your biological molecules
Dynamic Light Scattering (DLS) is a technique that allows researchers to accurately size their biologic molecules and determine the distribution of particle sizes in a solution. In order to turn scatt
-
25:01
How to find promising small molecule lead compounds with biophysical tools
Watch this webinar if you’re working in the field of small molecule drug discovery and want to learn how scientists in this field use biophysical tools to search for the most promising lead compounds.
-
28:21
How Abbvie's preformulation department assesses Drug-Like Properties of their antibody candidates
Join Dr. Brittney Mills as she explains what criteria AbbVie’s preformulation department screens for in their antibody candidates.
-
14:01
How to study molecular interactions of membrane proteins without compromising their native structure
The desire to use technology that allows you to study membrane proteins in close-to-native conditions is specifically important when it comes to interaction measurements. It’s always a question how mu
-
12:06
How to find expression and purification conditions that result in high levels of thermally stable membrane proteins
What you’ll learn It’s very common to experience low expression levels when producing membrane proteins — plus they’re finicky and unstable when they're outside of their native environment. Just know
-
56:52
Adventures in drug discovery - The quest for your best small molecule
Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com
-
35:47
Improve your protein degrader design with new ways to discover E3 ligase ligands
Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
-
35:24
Effect of different SARS-CoV-2 variants on COVID 19 assays and vaccines
SARS-CoV-2, the causative agent of COVID-19, has an ssRNA genome of almost 30kb that encodes for a total of 26 proteins. Among the four structural viral protein, in particular the S protein stands out
- Contact Specialist
-
33:11
Maximize stability & function of SARS-CoV-spike protein and ACE2 receptor using Monolith & Prometheus
Dr. Leah Pandiscia and Dr. Daniel Turman review how to integrate the Prometheus Panta and Monolith instruments in a characterization workflow demonstration, showing how to maximize stability and funct
-
22:36
Confirmation of the "Conformation" is key for drug discovery and development
Hear how Dr. Sathya Venkataramani from Janssen Biotherapeutics maximized protein stability using the Prometheus in a real life case study about the design and characterization of antibody-based drugs.
-
29:22
Mechanisms for protein aggregation and stabilization in solution, during freezing and drying, and at interfaces
Learn about the causes of protein aggregation and how to implement the best solutions to enhance protein stability with Dr. John Carpenter from the University of Colorado. He presented as one of three
-
27:20
Molecular interactions - a simple framework: Energy, energy, energy
Explore the complexities and drivers of molecular interactions with Dr. Tom Laue from the University of New Hampshire. He presented as a keynote speaker in the Protein Stability & Function: Can't have
-
42:46
Tour Prometheus Panta: How to make your formulation workflow more efficient with multi-parameter stability characterization
Join this case study and walk through of Prometheus Panta. Make your formulation workflow more efficient and effective with simultaneous, multi-parameter stability characterization. What you’ll lear
-
1:06:54
Prometheus Panta: The next frontier in protein stability characterization
Join this e-demo on the Prometheus Panta. Learn how to collect thermal unfolding, particle sizing, and aggregation data on a single platform using the NIST mAb. The growing complexity of therapeutic
-
34:16
DLS easily explained: What it tells you about your protein
Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and see a few examples of how DLS gives you deeper insights.
-
38:40
Practical strategies for overcoming challenges in the development of AAV vectors for gene therapy
Gene therapy promises to treat and potentially cure a disease by correcting its underlying genetic cause. While gene therapies that utilize AAV vectors have shown encouraging results —including a few
-
Loading more...